Sort
10,766 grants matching “checkpoint inhibitor”
Nanocage-based systemic delivery of TGFβ trap for immunomodulation of brain neoplasms
$505,850Jung Soo Suk · Johns Hopkins University · R01 · FY2023 · NS
Dissecting the NRG4 hormonal checkpoint in metabolic liver disease
$505,838Jiandie D Lin · University Of Michigan At Ann Arbor · R01 · FY2020 · DK
GENOTOXIC RESPONSES
$505,837Trey Ideker · University Of California, San Diego · P50 · FY2013 · GM
TIGIT in acute kidney injury and repair
$505,269Sanjeev Noel · Johns Hopkins University · R01 · FY2023 · DK
Exploring novel therapeutic strategies for combinatory therapy to treat renal clear cell carcinomas
$505,159Weizhou Zhang · University Of Florida · R01 · FY2023 · CA
Project 2 - Preclinical studies: Overcoming tumor heterogeneity
$505,053Steven Mark Albelda · University Of Pennsylvania · P01 · FY2022 · CA
An Environmental Chemical Receptor, the AhR, as a Mediator of Multiple Immune Checkpoints in Oral Cancer
$504,865David H Sherr · Boston University Medical Campus · R01 · FY2023 · ES
Project 2 - Preclinical studies: Overcoming tumor heterogeneity
$504,690Steven Mark Albelda · University Of Pennsylvania · P01 · FY2019 · CA
Inhibiting Multi-Functional ALDOA for Cancer Therapy
$504,587Garth Powis · Phusis Therapeutics, Inc. · R01 · FY2021 · CA
Role of Meis1 in Regulation of Cardiomyocyte Proliferation
$504,559Hesham Sadek · Ut Southwestern Medical Center · R01 · FY2015 · HL
Nanoscale Metal-Organic Frameworks Enable Radiotherapy-Radiodynamic Therapy and Deliver CpG Oligodeoxynucleotides to Generate Tumor Vaccines and Potentiate Immunotherapy of Head and Neck Cancers
$504,359Wenbin Lin · University Of Chicago · R01 · FY2021 · CA
Role of histotripsy synergized CD40 signaling in the re-engineering of cold tumors
$504,109Ashish Ranjan · Ut Southwestern Medical Center · R01 · FY2025 · CA
Project 4: Translation and preclinical studies of a personalized pancreas cancer vaccine
$503,987William E Gillanders · Washington University · P50 · FY2018 · CA
AHR-mediated immunosuppression in glioblastoma
$503,741Francisco J. Quintana · Brigham And Women'S Hospital · R01 · FY2019 · ES
Mechanisms of Tumor Derived Neutrophil Induced Apoptosis in Lymphocytes
$503,575A. McGarry Houghton · Fred Hutchinson Cancer Research Center · R01 · FY2018 · CA
Development of a novel biodegradable inorganic nanoparticle therapeutic for cancer
$503,511Jin Xie · University Of Georgia · R01 · FY2024 · CA
âPharmacologic targeting of NR4A1 and NR4A2 to activate glioblastoma treatment responseâ
$503,363Robert C Rostomily · Methodist Hospital Research Institute · R01 · FY2023 · NS
Characterizing and Targeting BAX- and BAK-Dependent Cell Death in Cancer
$503,337Emily H Cheng · Sloan-Kettering Inst Can Research · R01 · FY2023 · CA
Characterizing and Targeting BAX- and BAK-Dependent Cell Death in Cancer
$503,337Emily H Cheng · Sloan-Kettering Inst Can Research · R01 · FY2022 · CA
Protein Kinase Signaling and Cell Cycle Control
$503,262Michael B Yaffe · Massachusetts Institute Of Technology · R01 · FY2016 · ES
Protein Kinase Signaling and Cell Cycle Control
$503,262Michael B Yaffe · Massachusetts Institute Of Technology · R01 · FY2013 · ES
Protein Kinase Signaling and Cell Cycle Control
$503,262Michael B Yaffe · Massachusetts Institute Of Technology · R01 · FY2015 · ES
Protein Kinase Signaling and Cell Cycle Control
$503,262Michael B Yaffe · Massachusetts Institute Of Technology · R01 · FY2017 · ES
Targeting posttranslational modifications of B7-H4 in carcinogenesis and therapy
$503,234Yong Wan · Emory University · R01 · FY2025 · CA
Assessing the efficacy of a ROR1:PD-L1:CD2 multispecific T cell engager in ROR1-positive and -negative neuroblastoma models
$503,194James M Olson · Seattle Children'S Hospital · R21 · FY2024 · CA